Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce, and market innovative solutions and services in more than 110 countries.
Pioneers in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest. It transforms collected plasma into essential medicines to treat chronic, rare, prevalent and, at times, life-threatening conditions. To ensure a safe and consistent source of plasma-derived medicines worldwide, we have a vertically integrated production process, from plasma collection through fractionation and purification.
Key essential plasma-derived products include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and specialty hyperimmune globulins.
Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.
For more information, please visit grifols.com